RFG Advisory LLC Takes $1.30 Million Position in Genmab A/S Sponsored ADR $GMAB

RFG Advisory LLC purchased a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,318 shares of the company’s stock, valued at approximately $1,298,000.

Several other institutional investors and hedge funds also recently bought and sold shares of GMAB. Orbis Allan Gray Ltd raised its stake in shares of Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after acquiring an additional 2,209,659 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after purchasing an additional 2,084,966 shares during the last quarter. ABC Arbitrage SA purchased a new stake in Genmab A/S in the 2nd quarter worth about $9,236,000. Federated Hermes Inc. purchased a new stake in Genmab A/S in the 3rd quarter worth about $12,972,000. Finally, JPMorgan Chase & Co. lifted its stake in Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after purchasing an additional 135,814 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 1.8%

Shares of NASDAQ GMAB opened at $30.06 on Thursday. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $35.43. The firm has a market cap of $19.31 billion, a PE ratio of 12.79, a price-to-earnings-growth ratio of 17.96 and a beta of 0.90. The business has a fifty day simple moving average of $32.44 and a two-hundred day simple moving average of $29.61.

Wall Street Analysts Forecast Growth

GMAB has been the topic of a number of analyst reports. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Truist Financial restated a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Genmab A/S in a report on Wednesday, January 28th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.